Association of Medicaid Expansion With Timely Receipt of Treatment and Survival Among Patients With HR-Negative, HER2-Positive Breast Cancer
Medicaid expansion was associated with improved care and survival for patients with HR-negative, HER2-positive breast cancer, an aggressive cancer type for which prognosis largely depends on access to effective treatment.
Authors
- K. Robin Yabroff (ORCID: https://orcid.org/0000-0003-0644-5572)
- Xu Ji (ORCID: https://orcid.org/0000-0003-3025-3984)
- Kathryn J. Ruddy (ORCID: https://orcid.org/0000-0001-6298-332X)
- Sharon M. Castellino (ORCID: https://orcid.org/0000-0001-8367-2002)
- Changchuan Jiang (ORCID: https://orcid.org/0000-0002-7392-4154)
- Kewei Sylvia Shi (ORCID: https://orcid.org/0000-0002-0024-4916)
- Xuesong Han (ORCID: https://orcid.org/0000-0001-7159-7949)
Institutions
- American Cancer Society (US)
- Emory University (US)
- Aflac (United States) (US)
- Mayo Clinic in Arizona (US)
- Children's Healthcare of Atlanta (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Journal of the National Comprehensive Cancer Network
- Published
- 2024-10-24
- DOI
- https://doi.org/10.6004/jnccn.2024.7041
- Citations
- 6
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 6.78
Funders
- AstraZeneca
- Flatiron Health
- National Institutes of Health
- National Cancer Institute